{"name":"Janssen Pharmaceutical K.K.","slug":"janssen-pharmaceutical-kk","ticker":"","exchange":"","domain":"janssenkk.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":12,"colorKey":"cardiovascular","drugs":[{"name":"Erdafitinib Intravesical Delivery System","genericName":"Erdafitinib Intravesical Delivery System","slug":"erdafitinib-intravesical-delivery-system","indication":"Other","status":"phase_1"},{"name":"ITCZ-IV","genericName":"ITCZ-IV","slug":"itcz-iv","indication":"Invasive aspergillosis","status":"phase_3"},{"name":"JNJ 10229570-AAA 3.6%","genericName":"JNJ 10229570-AAA 3.6%","slug":"jnj-10229570-aaa-3-6","indication":"Other","status":"phase_1"},{"name":"JNJ-212082","genericName":"JNJ-212082","slug":"jnj-212082","indication":"Other","status":"phase_1"},{"name":"JNJ-54861911, 50 mg","genericName":"JNJ-54861911, 50 mg","slug":"jnj-54861911-50-mg","indication":"Other","status":"phase_2"},{"name":"JNJ-56021927 120 Milligram","genericName":"JNJ-56021927 120 Milligram","slug":"jnj-56021927-120-milligram","indication":"Other","status":"phase_1"},{"name":"JNJ-56021927 240 Milligram","genericName":"JNJ-56021927 240 Milligram","slug":"jnj-56021927-240-milligram","indication":"Other","status":"phase_1"},{"name":"JNJ-56021927 60 Milligram","genericName":"JNJ-56021927 60 Milligram","slug":"jnj-56021927-60-milligram","indication":"Other","status":"phase_1"},{"name":"JNS001","genericName":"JNS001","slug":"jns001","indication":"Other","status":"phase_3"},{"name":"Placebo A (After CP)","genericName":"Placebo A (After CP)","slug":"placebo-a-after-cp","indication":"Other","status":"phase_3"},{"name":"Placebo B (After CP)","genericName":"Placebo B (After CP)","slug":"placebo-b-after-cp","indication":"Other","status":"phase_3"},{"name":"Tramadol Hydrochloride; JNS013","genericName":"Tramadol Hydrochloride; JNS013","slug":"tramadol-hydrochloride-jns013","indication":"Other","status":"phase_2"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"CNTO 148","genericName":"CNTO 148","slug":"cnto-148","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"CNTO 1959","genericName":"CNTO 1959","slug":"cnto-1959","indication":"Psoriasis","status":"phase_2"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"JNS020QD","genericName":"JNS020QD","slug":"jns020qd","indication":"Type 2 diabetes","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"ITCZ Oral Solution","genericName":"ITCZ Oral Solution","slug":"itcz-oral-solution","indication":"Oropharyngeal candidiasis","status":"phase_3"}]}],"pipeline":[{"name":"CNTO 148","genericName":"CNTO 148","slug":"cnto-148","phase":"phase_3","mechanism":"CNTO 148 is a monoclonal antibody that blocks tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling in immune-mediated diseases.","indications":["Rheumatoid arthritis","Crohn's disease","Ulcerative colitis"],"catalyst":""},{"name":"JNS020QD","genericName":"JNS020QD","slug":"jns020qd","phase":"phase_3","mechanism":"JNS020QD is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"CNTO 1959","genericName":"CNTO 1959","slug":"cnto-1959","phase":"phase_2","mechanism":"CNTO 1959 is a monoclonal antibody that inhibits IL-23 signaling to reduce inflammatory immune responses.","indications":["Psoriasis","Inflammatory bowel disease"],"catalyst":""},{"name":"Erdafitinib Intravesical Delivery System","genericName":"Erdafitinib Intravesical Delivery System","slug":"erdafitinib-intravesical-delivery-system","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ITCZ Oral Solution","genericName":"ITCZ Oral Solution","slug":"itcz-oral-solution","phase":"phase_3","mechanism":"ITCZ (itraconazole) is an azole antifungal that inhibits fungal cytochrome P450-dependent lanosterol 14α-demethylase, disrupting ergosterol synthesis in the fungal cell membrane.","indications":["Oropharyngeal candidiasis","Esophageal candidiasis","Systemic fungal infections (aspergillosis, blastomycosis, histoplasmosis, cryptococcosis)"],"catalyst":""},{"name":"ITCZ-IV","genericName":"ITCZ-IV","slug":"itcz-iv","phase":"phase_3","mechanism":"ITCZ-IV is an intravenous formulation of itraconazole, a triazole antifungal that inhibits fungal cytochrome P450-dependent lanosterol 14α-demethylase, disrupting ergosterol synthesis in the fungal cell membrane.","indications":["Invasive aspergillosis","Blastomycosis","Histoplasmosis","Cryptococcosis"],"catalyst":""},{"name":"JNJ 10229570-AAA 3.6%","genericName":"JNJ 10229570-AAA 3.6%","slug":"jnj-10229570-aaa-3-6","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"JNJ-212082","genericName":"JNJ-212082","slug":"jnj-212082","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"JNJ-54861911, 50 mg","genericName":"JNJ-54861911, 50 mg","slug":"jnj-54861911-50-mg","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"JNJ-56021927 120 Milligram","genericName":"JNJ-56021927 120 Milligram","slug":"jnj-56021927-120-milligram","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"JNJ-56021927 240 Milligram","genericName":"JNJ-56021927 240 Milligram","slug":"jnj-56021927-240-milligram","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"JNJ-56021927 60 Milligram","genericName":"JNJ-56021927 60 Milligram","slug":"jnj-56021927-60-milligram","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"JNS001","genericName":"JNS001","slug":"jns001","phase":"phase_3","mechanism":"JNS001 is a monoclonal antibody that targets and inhibits a specific immune checkpoint or inflammatory pathway to modulate immune response.","indications":[],"catalyst":""},{"name":"Placebo A (After CP)","genericName":"Placebo A (After CP)","slug":"placebo-a-after-cp","phase":"phase_3","mechanism":"Placebo A is an inert control substance with no active pharmacological mechanism.","indications":[],"catalyst":""},{"name":"Placebo B (After CP)","genericName":"Placebo B (After CP)","slug":"placebo-b-after-cp","phase":"phase_3","mechanism":"Placebo B is an inert control substance with no active pharmacological mechanism.","indications":[],"catalyst":""},{"name":"Tramadol Hydrochloride; JNS013","genericName":"Tramadol Hydrochloride; JNS013","slug":"tramadol-hydrochloride-jns013","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":16,"phaseCounts":{"phase_3":7,"phase_2":3,"phase_1":6},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}